PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 3, 2018Blood185 citationsOpen Access

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

View Full Paper
FZFrancesca ZammarchiSCSimon CorbettLALauren Adams

Key Points

Key points are not available for this paper at this time.

Abstract

Key Points ADCT-402 is a CD19-targeted ADC delivering SG3199, a cytotoxic DNA minor groove interstrand crosslinking PDB dimer warhead. ADCT-402 has potent and selective antitumor activity against CD19-expressing hematological malignancies warranting clinical development.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zammarchi et al. (2018) studied this question.

synapsesocial.com/papers/6973f5a6c1b5f4eb45506cc7https://doi.org/10.1182/blood-2017-10-813493
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL2017 · 7 citations
  2. 2Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas2009 · 82 citations
  3. 3A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma2015 · 48 citations
  4. 4Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma2009 · 58 citations
  5. 5The 2016 revision of the World Health Organization classification of lymphoid neoplasms2016 · 7,899 citations